Payment overview · 2025
General Payments
$441.73
27 reported records · 9 companies
Healthcare provider profile · identity verified
Matthew A Beacom, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FREMONT, NE · NPI 1568476679
Verified facts
What the public records show
CMS Open Payments records show Matthew A Beacom, M.D. received $441.73 in general payments during 2025 across 27 reported records.
HARMONY BIOSCIENCES LLC accounted for 37.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $164.91 | 37.3% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.62 | 18.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.77 | 10.8% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $44.33 | 10.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.49 | 7.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.32 | 4.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.28 | 4.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.65 | 3.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.36 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $394.74 | 26 |
| Education | $46.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $117.92 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.77 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $44.83 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $44.33 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $36.79 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 250 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
250 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 384 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 323 | 59 |
| Furosemide | Furosemide | 306 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 298 | 53 |
| Gabapentin | Gabapentin | 263 | 41 |
| Eliquis | Apixaban | 250 | 38 |
| Sertraline Hcl | Sertraline Hcl | 201 | 33 |
| Potassium Chloride | Potassium Chloride | 200 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 50 |
| Tramadol Hcl | Tramadol Hcl | 181 | 46 |
| Lisinopril | Lisinopril | 156 | 38 |
| Omeprazole | Omeprazole | 135 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 24 |
| Meloxicam | Meloxicam | 126 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 23 |
| Donepezil Hcl | Donepezil Hcl | 122 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 21 |
| Lorazepam | Lorazepam | 94 | 21 |
| Memantine Hcl | Memantine Hcl | 94 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 18 |
| Alprazolam | Alprazolam | 90 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 13 |
| Famotidine | Famotidine | 90 | 19 |
| Losartan Potassium | Losartan Potassium | 90 | 19 |
| Allopurinol | Allopurinol | 89 | 15 |
| Simvastatin | Simvastatin | 88 | 26 |
| Prednisone | Prednisone | 87 | 24 |
| Carvedilol | Carvedilol | 83 | 26 |
| Metformin Hcl | Metformin Hcl | 82 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 17 |
| Metformin Hcl Er | Metformin Hcl | 74 | 14 |
| Jardiance | Empagliflozin | 73 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 72 | suppressed |
| Mirtazapine | Mirtazapine | 70 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 19 |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 58 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 57 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 16 |
| Montelukast Sodium | Montelukast Sodium | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 31 |
| Finasteride | Finasteride | 47 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 17 |
| Torsemide | Torsemide | 46 | 14 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Latanoprost | Latanoprost | 39 | suppressed |
| Nyamyc | Nystatin | 38 | 18 |
| Gemtesa | Vibegron | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 16 |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 12 |
| Baclofen | Baclofen | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 13 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Atenolol | Atenolol | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 13 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $441.73 · 27 records | HARMONY BIOSCIENCES LLC | ELIQUIS, Fluad, Flucelvax, GVOKE HYPOPEN, JARDIANCE, KISUNLA, NURTEC ODT, REXULTI, SPRAVATO, VRAYLAR, WAKIX, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error